In conclusione l’analisi ha dimostrato che Bexsero, ad un prezzo di acquisizione di €60 è costo efficace negli scenari 2, 3 e 4 quando si consideri la prospettiva della società.
E’ costo efficace negli scenari 2 e 4 anche nella prospettiva più conservativa del SSN. Negli altri scenari risulta costo efficace se il prezzo scende, a seconda dello scenario
Tabella 13
sTraTegy ToTal cosT (€) qaly losT incremenTal cosT (€) incremenTal qaly icer (€)*
icer (€)* compared
To no vaccinaTion
No Vaccination 61.934.036 2.275 -- -- Ref Ref Routine
2/4/6/12 I
(MenB Str 1) 144.949.539 425 83.015.503 1.850 44.872 44.872
prospeTTiva socieTà
Tabella 14
sTraTegy ToTal cosT (€) qaly losT incremenTal cosT (€) incremenTal qaly icer (€)*
icer (€)* compared
To no vaccinaTion
No Vaccination 82.542,802 4.305 -- -- Ref Ref Routine
2/4/6/12 I
(MenB Str 1) 149.328.726 787 66.785.924 3.517 18.988 18.988
prospeTTiva ssn
Tabella 15
sTraTegy ToTal cosT (€) qaly losT incremenTal cosT (€) incremenTal qaly icer (€)*
icer (€)* compared
To no vaccinaTion
No Vaccination 169.487.905 787 -- -- Ref Dominant Routine
2/4/6/12 I
(MenB Str 1) 192.792.834 4.305 23.304.928 -3.517 Dominated - 6.626
considerato, a valori al di sotto del prezzo di acquisizione di €60.
Scenario 1 Bexsero costo efficace ad un prezzo compreso tra €31 e €46
Scenario 2 Bexsero costo efficace ad un prezzo compreso tra €58 e €82
Scenario 3 Bexsero costo efficace ad un prezzo compreso tra €51 e €65
Scenario 4 Bexsero costo efficace ad un prezzo compreso tra €114 e €159
APPENDiCE A
Per il calcolo dell’incidenza delle malattie invasive da meningococco B, sono stati presi in considerazione i casi registrati attraverso il sistema di sorveglianza delle malattie batteriche invasive sommati ad una quota di casi non tipizzati (registrati nello stesso sistema) che si presume siano riconducibili al serogruppo B e rapportati alla popolazione di riferimento (ISTAT. Disponibile online al sito: http:// www.istat.it/it/popolazione (Ultimo accesso: 10.06.2013) per ogni anno di età preso in considerazione. Si è pertanto provveduto a calcolare i tassi di incidenza per ogni singolo anno di età della popolazione considerata.
year: 2005 - 2012 age
serogroup speciFiednoT 0 1-4 5-9 10-14 15-24 25-64 64+ ToTal
A 8 0 0 0 0 0 0 0 8 B 156 95 91 54 28 84 88 29 625 C 142 28 40 10 19 50 74 11 374 W 19 0 0 0 0 0 0 0 19 Y 36 0 0 0 0 0 0 0 36 Others 2 4 8 13 12 10 40 12 101 Not classified 161 21 36 21 16 41 31 9 336 ToTal 524 148 175 98 75 185 233 61 1,499
daTi di sorveglianza delle malaTTie baTTeriche invasive (aggiornaTi ad aprile 2013)
Bibliografia
[1] NICE. Bacterial meningitis and meningococcal septicaemia in children: Full guideline 2010;Available from: http://www.nice.org.uk/nicemedia/ live/13027/49437/49437.pdf.
[2] Wright, C., Wordsworth, R., Glennie, L. Counting the Cost of Meningitis. Meningitis Research Foundation. 2011. [3] Lucioni C, Alliata E, Mazzi S, Lizioli A. I costi
della meningite pneumococcica in età pediatrica. Pharmacoeconomics-Italian. Research Articles 2005; 7: 177-86.
[4] Istituto Nazionale di Statistica, ISTAT. Disponibile online al sito: http://www.istat.it/it/popolazione (Ultimo accesso: 10.02.2013).
[5] Taha MK and Deghmane AE, June 2012, in Vaccine: Development and Therapy, DovePress.
[6] Pouwels et al. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Human Vaccines & Immunotherapeutics 2013; 9:5, 1–10. [7] Christensen H, Hickman M, Edmunds WJ, Trotter
CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013 May 28;31(23):2638-46.
[8] Mathes T, Jacobs E,Morfeld JC, Pieper D. Methods of international health technology assessment agencies for economic evaluations- a comparative analysis. BMC Health Services Research 2013,13:371.
[9] AIES, Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia.
PharmacoEconomics - Italian Research Articles 2009; 11(2):83-93.
[10] Capri S, Ceci A., Terranova L. et al.Guidelines for economic evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Information Journal, 2001, 35:189-201.
[11] NICE: GUIDE TO METHODS TECHNOLOGY APPRAISAL 2013, disponibile online su: h t t p : / / w w w . n i c e . o r g . u k / m e d i a / D 4 5 / 1 E / GuideToMethodsTechnologyAppraisal2013.pdf. [12] SIMI. Risultati della sorveglianza delle malattie
batteriche invasive in Italia. Disponibile online: http://www.simi.iss.it/dati.htm.
[13] European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011.
[14] Azzari C, Canessa C, Lippi F, Moriondo M, Indolfi G, Nieddu F, Martini M, deMartino M, Castiglia P, Baldo V, Resti M; the Italian group for the study of Invasive Bacterial Disease. Distribution of invasive meningococcal B disease in Italian pediatric population: Implications for vaccination timing. Vaccine. 2013 Oct 8. doi:pii: S0264-410X(13)01325-X. 10.1016/j.vaccine.2013.09.055.
[15] Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, Schneerson R, Robbins JB, Miller MA. Comparative Long-term adverse effects elicited by invasive group B and C meningococcal infections. CID 2011;53:e117. [16] Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson
L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774-83.
[17] Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1.
[18] Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R. Predicted strain coverage of a meningococcal multicomponent vaccine (MenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013;13(5):416-25.
[19] Gossger N, Snape MD, Yu LM, Finn A, Bona G,
Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group.Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307(6):573-82.
[20] Thein HH, Gomes T, Krahn MD, Wodchis WP. Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. Qual Life Res 2010;19(1):81-9.
[21] Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791-9.
[22] Donev D, Zalatel-Kragelj, Bjegovic V, Burazeri G. Measuring the burden of disease: Disability Adjusted Life Year (DALY). Available at www.mf.uni-lj.si/.../6b 695fc9385e3e2ab8fb41ec7...
[23] Caban-Martinez AJ, Lee DJ, Fleming LE, Tancredi DJ, Arheart KL, LeBlanc WG, McCollister KE, Christ SL, Louie GH, Muennig PA. Arthritis, occupational class, and the aging US workforce. Am J Public Health. 2011;101(9):1729-34.
[24] Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, Lonnqvist J. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry. 2007;190:326-32. [25] Brown MM, Brown GC, Sharma S, Kistler J, Brown
H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327-31. [26] Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt
JJ, Kramers PGN, van de Water HPA et al. Disability weights for disease in The Netherlands. Amsterdan Medical Centre, Institute for Social Health Care, Amsterdam. 1997.
[27] Yfantopoulos J. Quality of life and QALYs in themeasurement of health. Archives of Hellenic Medicine 2001; 18(2) : 114-130.
[28] Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res. 2011;20(4):601-608.
[29] Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLOS Medicine 2012; 9(9) e1001307. [30] ISTAT. Rivaluta – Rivalutazioni e documentazione su
prezzi, costi e retribuzioni contrattuali. Reperibile al sito: http://rivaluta.istat.it/Rivaluta/. Accesso del 15 Febbraio 2013.
[31] AGENAS. Agenzia Nazionale per i Servizi Sanitari Regionali. Ricoveri ospedalieri. I sistemi tariffari regionali vigenti nell'anno 2009. Gennaio 2010. [32] www.torrinomedica.it.
[33] Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W-135 and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLOSone. 2013:e65036. [34] Olesen J, Gustavsson A, Svensson M, Wittchen HU,
Jönsson B; CDBE2010 study group; European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol. 2012 ;19(1):155-62.
[35] Oxford Economic. The economic costs of arthritis for the UK economy. Final report, March 2010.
[36] Guerrini R, Battini R, Ferrari AR, Veggiotti P, Besana D, Gobbi G, Pezzani M, Berta E, Tetto A, Beghi E, Monticelli ML, Tediosi F, Garattini L, Russo S, Rasmini P, Amadi A, Quarti P, Fabrizzi R. Epilepsy Collaborative Study Group. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia. 2001;42(5):641-6. [37] Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F;
EPICOS Group. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia. 2004;45(2):171-8. [38] Deambrosis P, Terrazzani G, Giusti P, Pullia G. Il costo
del paziente depresso: l’esperienza della Ulss 9 di Treviso. PharmacoEconomics Italian Research 2007;9: 1-8. [39] Gustavsson A, Svensson M, Jacobi F, Allgulander C,
Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C,
Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jonsson B, Olesen J; CDBE2010Study Group. Cost of disorders of the brain in Europe 2010. EurNeuropsychopharmacol. 2011 ;21(10):718-79. [40] Frick KD, Walt JG, Chiang TH, Doyle JJ, Stern LS,
Katz LM, Dolgitser M, Hendlish SK. Direct costs of blindness experienced by patients enrolled in managed care. Ophthalmology. 2008;115(1):11-7. [41] Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton
RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P. Cost of healthcare for patients with migraine in five Eupean countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361-378.
[42] Gopal I, Bhonagiri S, Ronco C, Bellomo R. Out of hospital outcome and quality of life in survivors of combined acute multiple organ and renal failure treated with continuous venovenous hemofiltration/ hemodiafiltration. Intensive.
[43] EUROSTAT, 2013 Disponibile online al sito: http:// epp.eurostat.ec.europa.eu/tgm/table.do?tab=table &init=1&language=en&pcode=tec00001&plugin=1 (Ultimo accesso 23.09.2013).